CO2022012916A2 - Formulaciones de anticuerpos anti protofibrillas aβ de alta concentración y métodos de uso de las mismas - Google Patents

Formulaciones de anticuerpos anti protofibrillas aβ de alta concentración y métodos de uso de las mismas

Info

Publication number
CO2022012916A2
CO2022012916A2 CONC2022/0012916A CO2022012916A CO2022012916A2 CO 2022012916 A2 CO2022012916 A2 CO 2022012916A2 CO 2022012916 A CO2022012916 A CO 2022012916A CO 2022012916 A2 CO2022012916 A2 CO 2022012916A2
Authority
CO
Colombia
Prior art keywords
methods
protofibril antibody
antibody formulations
concentration anti
protofibril
Prior art date
Application number
CONC2022/0012916A
Other languages
English (en)
Spanish (es)
Inventor
Nobuo Yoshida
Naomi Sakuramoto
Takahisa Sakaguchi
Hirokazu Kito
Takahiro Ozawa
Anjali Joshi
Yung Yueh Hsu
Pierre Souillac
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75746958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2022012916(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CO2022012916A2 publication Critical patent/CO2022012916A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
CONC2022/0012916A 2020-03-20 2022-09-12 Formulaciones de anticuerpos anti protofibrillas aβ de alta concentración y métodos de uso de las mismas CO2022012916A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992746P 2020-03-20 2020-03-20
US202063027263P 2020-05-19 2020-05-19
PCT/IB2021/000155 WO2021186245A1 (en) 2020-03-20 2021-03-19 HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
CO2022012916A2 true CO2022012916A2 (es) 2022-09-20

Family

ID=75746958

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0012916A CO2022012916A2 (es) 2020-03-20 2022-09-12 Formulaciones de anticuerpos anti protofibrillas aβ de alta concentración y métodos de uso de las mismas

Country Status (28)

Country Link
US (1) US20230183328A1 (cg-RX-API-DMAC7.html)
EP (2) EP4252777B1 (cg-RX-API-DMAC7.html)
JP (2) JP7689141B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220156534A (cg-RX-API-DMAC7.html)
CN (1) CN115315251A (cg-RX-API-DMAC7.html)
AU (1) AU2021238951A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018766A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174778A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002517A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022012916A2 (cg-RX-API-DMAC7.html)
DK (1) DK4121007T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041762T3 (cg-RX-API-DMAC7.html)
FI (1) FI4121007T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251087T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072937T2 (cg-RX-API-DMAC7.html)
IL (2) IL326613A (cg-RX-API-DMAC7.html)
LT (1) LT4121007T (cg-RX-API-DMAC7.html)
MA (1) MA59082B1 (cg-RX-API-DMAC7.html)
MD (1) MD4121007T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022011101A (cg-RX-API-DMAC7.html)
PH (1) PH12022552172A1 (cg-RX-API-DMAC7.html)
PL (1) PL4121007T3 (cg-RX-API-DMAC7.html)
PT (1) PT4121007T (cg-RX-API-DMAC7.html)
RS (1) RS67249B1 (cg-RX-API-DMAC7.html)
SI (1) SI4121007T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500350T1 (cg-RX-API-DMAC7.html)
TW (1) TWI923576B (cg-RX-API-DMAC7.html)
WO (1) WO2021186245A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
JP2024525559A (ja) 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
KR20240142535A (ko) 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
CN120202218A (zh) 2022-11-28 2025-06-24 卫材R&D管理有限公司 使用tau PET水平的治疗方法
IL324807A (en) 2023-06-09 2026-01-01 Eisai R&D Man Co Ltd Treatment methods using anti-Abeta protofibril antibody
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
WO2020023530A2 (en) * 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease

Also Published As

Publication number Publication date
SI4121007T1 (sl) 2025-10-30
DK4121007T3 (da) 2025-09-22
EP4121007B1 (en) 2025-07-02
IL326613A (en) 2026-04-01
MA59082B1 (fr) 2025-09-30
CL2022002517A1 (es) 2023-03-24
JP2023518066A (ja) 2023-04-27
SMT202500350T1 (it) 2025-11-10
IL295383A (en) 2022-10-01
JP7689141B2 (ja) 2025-06-05
EP4252777B1 (en) 2026-06-17
KR20220156534A (ko) 2022-11-25
CA3174778A1 (en) 2021-09-23
JP2025111516A (ja) 2025-07-30
EP4121007A1 (en) 2023-01-25
TWI923576B (zh) 2026-05-01
FI4121007T3 (fi) 2025-09-11
MX2022011101A (es) 2022-10-03
PT4121007T (pt) 2025-09-25
US20230183328A1 (en) 2023-06-15
EP4252777A2 (en) 2023-10-04
HRP20251087T1 (hr) 2025-11-07
TW202200201A (zh) 2022-01-01
CN115315251A (zh) 2022-11-08
LT4121007T (lt) 2025-09-25
IL295383B1 (en) 2026-04-01
IL295383B2 (en) 2026-08-01
HUE072937T2 (hu) 2025-12-28
ES3041762T3 (en) 2025-11-14
EP4252777A9 (en) 2023-11-15
AU2021238951A1 (en) 2022-10-20
PL4121007T3 (pl) 2025-11-03
WO2021186245A1 (en) 2021-09-23
PH12022552172A1 (en) 2023-12-11
EP4252777A3 (en) 2024-01-24
MD4121007T2 (ro) 2025-11-30
BR112022018766A2 (pt) 2022-11-01
RS67249B1 (sr) 2025-10-31
CL2024003428A1 (es) 2025-04-11

Similar Documents

Publication Publication Date Title
CL2022002517A1 (es) Formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
CO2017013231A2 (es) Composiciones que comprenden una cepa bacteriana del género parabacteroides
MX2019003593A (es) Composiciones de vacuna neumococica multivalente que comprenden conjugados de polisacaridos y proteinas.
MX2022005732A (es) Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina.
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CY1114185T1 (el) Υποδοριο σκευασμα αντισωματος αντι-her2
BR112017024517A2 (pt) compostos de tetraidroquinolinona como moduladores ror gama
AR115721A1 (es) Anticuerpos que comprenden un polipéptido insertado en la región marco 3
AR132698A1 (es) DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN)
MX2021006012A (es) Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.
AR122352A1 (es) Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este
CR20250060A (es) Anticuerpos anti monometil auristatina y fragmentos de anticuerpos.
CL2022001795A1 (es) Terapia combinada de inhibidores de cd73 e inhibidores de los receptores de adenosina a2a/a2b.
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
PH12021550617A1 (en) Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
MX2024001396A (es) Conjugados anticuerpo-fármaco y métodos de uso de estos.
AR118778A1 (es) Formulación de anticuerpo
MX2021013347A (es) Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina.
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
CL2023003209A1 (es) Composición farmacéutica de pembrolizumab y su uso
MX2023000601A (es) Composicion farmaceutica acuosa que comprende un antagonista del receptor p2y12.
MX2021015561A (es) Composiciones farmaceuticas que contienen dapansutrilo.